Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 17516390.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Alemtuzumab is a lymphocyte ablative agent that may cause susceptibility to severe opportunistic infections similar to those seen in AIDS. Pathogen-specific immune reconstitution syndromes can complicate antiretroviral therapy and immune recovery in HIV-infected patients. We present the first reported case of immune reconstitution syndrome associated with T lymphocyte recovery after alemtuzumab therapy.
Medical subject headings
- Antibodies, Monoclonal
- Antibodies, Neoplasm
- Antineoplastic Agents
- Cryptococcus neoformans
- Immune System Diseases
- Leukemia, Prolymphocytic
- Leukemia, T-Cell